

## Curriculum Vitae

|                                                                                  |                                                       |                                                     |
|----------------------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|
|  | <b>Name</b><br>(First Name / Middle Name / Last Name) | Jie Liang                                           |
|                                                                                  | <b>Title</b><br>(Prof. Dr., etc.)                     | Prof.                                               |
|                                                                                  | <b>Affiliation</b>                                    | Xijing Hospital of Digestive Diseases, Xi'an, China |
|                                                                                  | <b>Country</b>                                        | China                                               |
|                                                                                  | <b>E-mail</b>                                         | liangjie@fmmu.edu.cn; conciselj@126.com             |

### Educational Background

|                 |                                           |          |
|-----------------|-------------------------------------------|----------|
| 1998.09-2003.06 | Fourth Military Medical University, China | M.D      |
| 2003.09-2008.06 | Fourth Military Medical University, China | Ph.D     |
| 2009.02-2012.08 | Virgina Common Wealth University, USA     | Post Doc |

### Professional Career

|                 |                                                   |                               |
|-----------------|---------------------------------------------------|-------------------------------|
| 2008.06-2012.12 | Department of Digestive Diseases, Xijing Hospital | Attending physician& Lecturer |
| 2012.12-2017.12 | Department of Digestive Diseases, Xijing Hospital | Associated Professor          |
| 2018.12-now     | Department of Digestive Diseases, Xijing Hospital | Full Professor                |

### Research Fild

IBD, GI cancer, FGID

### Main Scientific Publications

1. Wang F, Zhou H, Zhang Y, Da Y, Zhang T, Shi Y, Wu T, Liang J. Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn's disease. Sci Rep. 2025 Jan 15;15(1):1984. doi: 10.1038/s41598-024-82855-0. (JCR: Q2, IF=4.6, Corresponding-author)
2. Zhang J, Li R, Chen L, Wang F, Zhou H, Liu X, Fan Z, Shi Y, Wu T, Wu K, Liang J. Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD Center: a monocentric study. Clin Exp Med. 2024 Sep 30;24(1):233. doi: 10.1007/s10238-024-01468-z. (JCR: Q3, IF=3.2, Corresponding-author)
3. 4. Fan Z, Shi Y, Liang J. The Mysterious Cause of Refractory Diarrhea and Weight Loss in a Young Woman. Gastroenterology. 2024 Jul 9:S0016-5085(24)05206-5. doi: 10.1053/j.gastro.2024.07.003. Epub ahead of print. PMID: 38992450. (JCR: Q1, IF=25.7, Corresponding-author)
4. 5. Wan J, Shen J, Zhong J, Ge W, Miao Y, Zhang X, Wen Z, Wang Y, Liang J, Wu K. Natural course of ulcerative

- colitis in China: Differences from the West? United European Gastroenterol J. 2024 Jul 19. doi: 10.1002/ueg2.12634. Epub ahead of print. PMID: 39031457. (JCR: Q2, IF=5.8,)
6. Li RX, Wu T, Li XF, Zhou H, Shi YT, Wang F, Liang J. Inadequate pregnancy-specific knowledge among patients with inflammatory bowel disease: A multicenter survey in China. J Dig Dis. 2024 Feb;25(2):100-108. doi: 10.1111/1751-2980.13258. PMID: 38599672. (JCR: Q2, IF=3.5, Corresponding-author)
7. 8. Li X, Wang F, Jia Y, Zhou H, Shi Y, Tian F, Chen Y, Liang J. The change of healthcare service in Chinese patients with inflammatory bowel disease during the pandemic: a national multicenter cross-sectional study. Sci Rep. 2023 Nov 16;13(1):20084. doi: 10.1038/s41598-023-46892-5. PMID: 37973924; PMCID: PMC10654896. (JCR: Q2, IF=4.6, Corresponding-author)
9. Wang F, Li X, Shi Y, Zhou H, Yang G, Li R, Wu T and Liang J. Efficacy and safety of ada-limumab biosimilar (HS016) in inflammatory bowel disease from the real-world study. Front Pharmacol. 2023;14:1259183. doi: 10.3389/fphar.2023.1259183 (JCR: Q1, IF=5.6, Corresponding-author)
10. Li R, Li X, Zhou H, Shi Y, Wang F, Wu T, Liang J. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review. Front Immunol. 2023 May 23;14:1205046. doi: 10.3389/fimmu.2023.1205046. PMID: 37287984; PMCID: PMC10242066. (JCR: Q1, IF=7.3, Corresponding-author)
11. Zhou H, Wang F, Wan J, Su S, Shi Y, Li X, Wu T, Liang J. Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries. J Clin Med. 2023 Feb 27;12(5):1894. doi: 10.3390/jcm12051894. PMID: 36902681; PMCID: PMC10004158. (JCR: Q2, IF=3.9, Corresponding-author)
12. Cao Y, Cheng K, Yang M, Deng Z, Ma Y, Yan X, Zhang Y, Jia Z, Wang J, Tu K, Liang J, Zhang M. Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease. J Nanobiotechnology. 2023 Jan 19;21(1):21. doi: 10.1186/s12951-023-01770-0. PMID: 36658555; PMCID: PMC9854161. (JCR: Q1, IF=10.2, Co-Corresponding-author)
13. Ma Y, Zhao J, Cheng L, Li C, Yan X, Deng Z, Zhang Y, Liang J, Liu C, Zhang M. Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics. Carbon, 2023, 204:526-537. DOI:10.1016/j.carbon.2023.01.006. (JCR: Q1, IF=10.9, Co-Corresponding-author).
14. 16. Han Y, Gao X, Wu N, Jin Y, Zhou H, Wang W, Liu H, Chu Y, Cao J, Jiang M, Yang S, Shi Y, Xie X, Chen F, Han Y, Qin W, Xu B, Liang J. Long noncoding RNA LINC00239 inhibits ferroptosis in colorectal cancer by binding to Keap1 to stabilize Nrf2. Cell Death Dis. 2022 Aug 29;13(8):742. doi: 10.1038/s41419-022-05192-y. PMID: 36038548; PMCID: PMC9424287. (JCR: Q1, IF=9.0, Corresponding-author)
15. 60. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Al-legood JC, Price MM, Avni D, Takabe K, Kordula T, Milstien S, Spiegel S. Sphingosine-1-Phosphate Links Persistent STAT3 Activation, Chronic Intestinal Inflammation, and Development of Colitis-Associated Cancer. Cancer Cell. 2013;23(1):17-20. PMID: 23273921 (JCR: Q1, IF=23.893, First-author)